NI201400128A - Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de farmaco anti-cancerígenos. - Google Patents

Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de farmaco anti-cancerígenos.

Info

Publication number
NI201400128A
NI201400128A NI201400128A NI201400128A NI201400128A NI 201400128 A NI201400128 A NI 201400128A NI 201400128 A NI201400128 A NI 201400128A NI 201400128 A NI201400128 A NI 201400128A NI 201400128 A NI201400128 A NI 201400128A
Authority
NI
Nicaragua
Prior art keywords
cancer cells
optical density
well
well plate
drug
Prior art date
Application number
NI201400128A
Other languages
English (en)
Inventor
Perree Mathieu
E Hallquist Allan
Petit Olivier
Original Assignee
Diatech Oncology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201400128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Diatech Oncology filed Critical Diatech Oncology
Publication of NI201400128A publication Critical patent/NI201400128A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/59—Transmissivity
    • G01N21/5907—Densitometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Software Systems (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

Se provee un sistema de computadora para determinar la efectividad relativa de fármacos anti-cancerígenos. La interfase tiene opciones seleccionables, incluyendo una opción para mejorar los parámetros de prueba del fármaco, y permite al usuario la selección de parámetros de prueba de fármaco deseados con relación a una placa con pocillos virtual asociada con una placa de pocillos física de un espectrofotómetro. El sistema de computadora causa que el espectrofotómetro inicie una prueba de fármaco, en donde la placa de pocillos física incluye al menos un pocillo de prueba que contiene células cancerígenas viables; y al menos un fármaco candidato en una concentración predeterminada; y al menos un pocillo de control con las células cancerígenas viables sola. El sistema registra la densidad óptica del pocillo a una longitud de onda predeterminada a intervalos de tiempo seleccionados por una duración de tiempo seleccionada, y almacena las mediciones de la densidad óptica y tiempo en la base de datos. Se calcula un valor de actividad de las mediciones de la densidad óptica y tiempo, y se despliega una correlación entre el valor de la actividad y la habilidad del fármaco candidato para inducir apoptosis en las células cancerígenas.
NI201400128A 2012-05-02 2014-10-31 Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de farmaco anti-cancerígenos. NI201400128A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641610P 2012-05-02 2012-05-02
US13/803,623 US9476871B2 (en) 2012-05-02 2013-03-14 System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Publications (1)

Publication Number Publication Date
NI201400128A true NI201400128A (es) 2015-11-24

Family

ID=49514877

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400128A NI201400128A (es) 2012-05-02 2014-10-31 Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de farmaco anti-cancerígenos.

Country Status (23)

Country Link
US (3) US9476871B2 (es)
EP (2) EP4134962A1 (es)
JP (1) JP6365988B2 (es)
KR (1) KR102028711B1 (es)
CN (1) CN104412270B (es)
AU (2) AU2013256248B2 (es)
BR (1) BR112014027287A2 (es)
CA (1) CA2872109C (es)
CL (1) CL2014002981A1 (es)
CO (1) CO7190233A2 (es)
CR (1) CR20140551A (es)
CU (1) CU20140125A7 (es)
HK (1) HK1203670A1 (es)
IL (1) IL235455B (es)
MX (1) MX345540B (es)
NI (1) NI201400128A (es)
NZ (1) NZ702526A (es)
PE (1) PE20150299A1 (es)
PH (1) PH12014502687A1 (es)
RU (1) RU2014148543A (es)
SG (1) SG11201407141VA (es)
TW (1) TWI605413B (es)
WO (1) WO2013166233A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
CA2873180A1 (en) * 2012-05-15 2013-11-21 Diatech Oncology Tumor cell isolation/purification process and methods for use thereof
US9460407B2 (en) * 2013-05-03 2016-10-04 Sap Se Generating graphical representations of data
WO2015171848A2 (en) * 2014-05-08 2015-11-12 Diatech Oncology, Llc Synergism and antagonism between multiple anti-cancer agents determined by mick assay
JP6521528B2 (ja) * 2016-04-18 2019-05-29 富士フイルム株式会社 代替医薬品検索装置及び代替医薬品検索方法
US11151604B2 (en) * 2016-06-10 2021-10-19 International Business Machines Corporation Revenue management using dynamic customer selection
CN110047562B (zh) * 2019-05-14 2021-04-27 上海上药第一生化药业有限公司 一种基于酶活力测定法的效价检测的信息化结构和方法
US20200388355A1 (en) * 2019-06-07 2020-12-10 Cary A. Presant Method and devices for direct apoptosis assay of purified cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068181A (en) 1989-12-01 1991-11-26 Akzo N.V. Method of monitoring reagent delivery in a scanning spectrophotometer
US5356793A (en) 1990-03-15 1994-10-18 Nitta Gelatin Inc. Method for testing the sensitivity of anticancer drug
US6077684A (en) 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
CN1220395A (zh) * 1997-12-15 1999-06-23 中国科学院生物物理研究所 一种基于微量元素分布特征的抗癌药物筛选方法
US6448030B1 (en) 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
WO2002040702A2 (en) * 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002239771A1 (en) 2000-11-13 2002-06-18 Vanderbilt University Methods of predicting chemotherapy response
EP1344060A4 (en) 2000-11-17 2004-12-22 Alfred E Slanetz METHOD FOR DETERMINING THE FUNCTION OF TARGETS AND IDENTIFYING SERIAL HEADS OF DRUGS
AU2002238874A1 (en) 2002-03-13 2003-09-22 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
US6900058B2 (en) 2003-03-11 2005-05-31 Bionostics, Inc. Control solution for photometric analysis
US8021611B2 (en) 2005-04-09 2011-09-20 ProteinSimple Automated micro-volume assay system
CN1954887A (zh) * 2005-10-28 2007-05-02 中国科学院大连化学物理研究所 一种体外抗癌药物筛选模型的制备方法
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
KR100721927B1 (ko) 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
US20100042351A1 (en) 2008-07-10 2010-02-18 Covey Todd M Methods and apparatus related to management of experiments
US20120224053A1 (en) * 2009-06-17 2012-09-06 Board Of Regents, The University Of Texas System Method and apparatus for quantitative microimaging
KR101533469B1 (ko) 2010-02-03 2015-07-02 연세대학교 산학협력단 Ｒａｓ의 Ｔｈｒ-144번과 Ｔｈｒ-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
US8475739B2 (en) * 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
CA2873180A1 (en) 2012-05-15 2013-11-21 Diatech Oncology Tumor cell isolation/purification process and methods for use thereof

Also Published As

Publication number Publication date
CU20140125A7 (es) 2015-05-28
SG11201407141VA (en) 2014-11-27
BR112014027287A2 (pt) 2017-08-08
CN104412270A (zh) 2015-03-11
EP4134962A1 (en) 2023-02-15
CO7190233A2 (es) 2015-02-19
CA2872109A1 (en) 2013-11-07
AU2013256248A1 (en) 2015-01-15
AU2018282460A1 (en) 2019-01-24
CA2872109C (en) 2019-08-20
WO2013166233A1 (en) 2013-11-07
TW201349161A (zh) 2013-12-01
IL235455B (en) 2018-03-29
US20140141462A1 (en) 2014-05-22
PE20150299A1 (es) 2015-02-25
US20170219563A1 (en) 2017-08-03
NZ702526A (en) 2017-05-26
CR20140551A (es) 2015-02-23
CL2014002981A1 (es) 2015-09-11
US20200249222A1 (en) 2020-08-06
AU2018282460B2 (en) 2020-12-10
CN104412270B (zh) 2018-03-20
RU2014148543A (ru) 2016-06-27
EP2847701A4 (en) 2016-01-06
AU2013256248B2 (en) 2018-10-04
MX345540B (es) 2017-02-03
MX2014013271A (es) 2015-04-08
JP2015524046A (ja) 2015-08-20
US10488402B2 (en) 2019-11-26
PH12014502687A1 (en) 2015-01-26
JP6365988B2 (ja) 2018-08-01
KR102028711B1 (ko) 2019-10-04
TWI605413B (zh) 2017-11-11
EP2847701A1 (en) 2015-03-18
KR20150023337A (ko) 2015-03-05
HK1203670A1 (en) 2015-10-30
US9476871B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
NI201400128A (es) Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de farmaco anti-cancerígenos.
CL2017003233A1 (es) Proceso y sistema de analisis de la condicion del suelo
ES2666879T3 (es) Recuperación de posición por medio de modelos de rellanos ficticios
Sehgal et al. Basal cell carcinoma: pathophysiology.
CO2019008341A2 (es) Análisis de señales múltiples para la identificación de ámbito afectado
CL2016001867A1 (es) Sistema y dispositivo para la generación de alto rendimiento de gotitas y métodos de uso combinatorios.
PE20180776A1 (es) Ensayos interrogatorios basados en celulas y usos de los mismos
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
BR112012022773A2 (pt) sistema, método e interface de apresentação para a verificação e gerenciamento da distribuição e vendas de medicamento
AR091091A1 (es) Modelado estratigrafico utilizando perfiles de densidad de datos de produccion
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
CL2015002572A1 (es) Marcadores asociados con inhibidores de wnt
CR20160435A (es) Registro de radiación perjudicial potencial
Dumas et al. Hyperviscosity syndrome
CL2013002421A1 (es) Un sistema y metodo para distribuir alertas con respecto a un evento.
AR104805A1 (es) Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet
AR088276A1 (es) Fenotipificacion de precision usando analisis de proximidad del espacio de puntuacion
BR112015027371A2 (pt) Método para determinação de importância de atributos, e, dispositivo transportador de programa não transitório
Nowak et al. SELECTED ASPECTS OF TERAHERTZ SPECTROSCOPY IN PHARMACEUTICAL SCIENCES.
AR100922A1 (es) Sistema y método electroanalítico para medir analitos tales como azúcar, sulfitos, etanol, entre otros, cuya concentración es importante en el control de calidad del vino, empleando un mayor número de muestras, en el tiempo
Xiao et al. Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxel-treated HepG2 cells.
ES2601790T3 (es) Expositor de venta
Touchette et al. Identification of and intervention to address therapeutic gaps in care.
Yoo et al. The influence of attitude of inhibiting spousal disclosure about stress on the mental health of firefighters
Kuo et al. Evaluation of the safety and efficacy of warfarin in Taiwanese patients.